🇺🇸 FDA
Patent

US 12195447

Azolopyrimidine for the treatment of cancer-related disorders

granted A61KA61K31/506A61K31/5377

Quick answer

US patent 12195447 (Azolopyrimidine for the treatment of cancer-related disorders) held by Arcus Biosciences, Inc. expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arcus Biosciences, Inc.
Grant date
Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61K, A61K31/506, A61K31/5377, A61K45/06, A61P